Deguise, M-O, Baranello, G, Mastella, C, Beauvais, A, Michaud, J, Leone, A, De Amicis, R, Battezzati, A, Dunham, C, Selby, K, Chardon, J, McMillan, H, Huang, YT, Courtney, N, Mole, A, Kubinski, S, Claus, P, Murray, L, Bowerman, M ORCID:, Gillingwater, TH, Bertoli, S, Parsons, S and Kothary, R (2019) Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Annals of Clinical and Translational Neurology, 6 (8). pp. 1519-1532.

[img] Text
Deguise et al. ACTN submitted version July 2019.pdf - Accepted Version
Restricted to Repository staff only until 26 July 2020.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB)
M Bowerman - Abnormal fatty acid metabolism is a core component of spinal muscular atrophy.pdf - Published Version
Available under License Creative Commons Attribution.

Download (8MB) | Preview


Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra-neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease.

We analyzed clinical data collected from a large cohort of pediatric SMA type I-III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA.

We identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/- mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non-alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation.

This work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.

Item Type: Article
Additional Information: © 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine and Health Sciences > Institute for Science and Technology in Medicine
Depositing User: Symplectic
Date Deposited: 24 Jul 2019 11:33
Last Modified: 22 Aug 2019 10:13

Actions (login required)

View Item View Item